LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

LLY

1,142.12

-0.21%↓

JNJ

236.71

+1.9%↑

ABBV

225.17

+1.13%↑

UNH

412.34

+1.63%↑

MRK

119.37

+0.12%↑

Strona główna・Stock List・Hutchison China MediTech Ltd ADR

Hutchison China MediTech Ltd ADR

Closed

SectorHealthcare

10.52 -2.59

Buy Sell

Overview

Share price change

24h

Current

Min

10.34

Max

10.76

Key metrics
By Trading Economics
Income	227M
Sales	139M
P/E Sector Avg	4.094 49.888
Profit margin	163.843
Employees	1,796
EBITDA	1.3M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+54.84% upside

Market Stats
By TradingEconomics
Market Cap	1.9B
Previous open	13.11
Previous close	10.52

News Sentiment

By Acuity

10%

90%

8 / 344 Ranking in Healthcare

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

9 cze 2026, 23:49 UTC

Market Talk

Nikkei May Fall Following Tech Stock Declines on Wall Street -- Market Talk

9 cze 2026, 23:45 UTC

Acquisitions, Mergers, Takeovers

Correct: Sigma Healthcare: Has Engaged in Preliminary Discussions in Boots Sale Process

9 cze 2026, 23:44 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare Says No Certainty That Any Transaction Will Eventuate

9 cze 2026, 23:44 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare: Continuously Reviews Opportunities to Create Value For Shareholders

9 cze 2026, 23:43 UTC

Acquisitions, Mergers, Takeovers

Sigma Healthcare: Has Engaged in Preliminary Discussions to Sell Boots

9 cze 2026, 23:35 UTC

Market Talk

Oil Rises on Escalating Supply Disruption Concerns -- Market Talk

9 cze 2026, 22:06 UTC

Acquisitions, Mergers, Takeovers

Samsung: Element Has Expanded Rapidly Since 2022 Launch of AVITI

9 cze 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung: Element to Speed Commercialization of Gene-Sequencing Products

9 cze 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung: Additional Investment Makes It Largest Shareholder in Element

9 cze 2026, 22:05 UTC

Acquisitions, Mergers, Takeovers

Samsung Electronics Raises Stake in Element Biosciences With $175 Million Investment

9 cze 2026, 20:51 UTC

Earnings

Micron, Marvell, Super Micro, Coherent, Smucker, and More Stocks That Explain Today's Market -- Barrons.com

9 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

9 cze 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 cze 2026, 20:09 UTC

Market Talk

Cryptocurrency Traders Look for Bitcoin Bottom -- Market Talk

9 cze 2026, 19:36 UTC

Market Talk

Cattle Climbs as Crude Oil Falls -- Market Talk

9 cze 2026, 19:32 UTC

Market Talk

Barclays Oil Price Outlook Contingent on Hormuz Reopening -- Market Talk

9 cze 2026, 19:25 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trade -- Market Talk

9 cze 2026, 19:00 UTC

Market Talk

Oil Settles Lower on Continued Hopes for Middle East Deal -- Market Talk

9 cze 2026, 18:52 UTC

Acquisitions, Mergers, Takeovers

Warner Bros. Stock Hits a Low. Its Paramount Merger Return Is Getting Buzz. -- Barrons.com

9 cze 2026, 18:47 UTC

Market Talk

No World Cup Inflation Seen So Far in Mexico -- Market Talk

9 cze 2026, 18:37 UTC

Market Talk

Canada's Cooling Trade With the U.S. -- Market Talk

9 cze 2026, 18:27 UTC

Market Talk

Precious Metals Lower as Trump Vows Military Response -- Market Talk

9 cze 2026, 17:35 UTC

Market Talk

Treasury Yields, Dollar Briefly Rise on Trump's Iran Retaliation Threat -- Market Talk

9 cze 2026, 17:30 UTC

Market Talk

Trump Post on Apache Helicopter Causes Brief Spike in Oil -- Market Talk

9 cze 2026, 16:34 UTC

Market Talk

Cryptocurrency Weakness Follows Selling in Equities -- Market Talk

9 cze 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9 cze 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9 cze 2026, 16:20 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Health Care Roundup: Market Talk

9 cze 2026, 15:28 UTC

Market Talk

Gold Futures Fall Further as Rate Fears Prevail -- Market Talk

9 cze 2026, 15:25 UTC

Market Talk

Oil Extends Losses, Falling More Than 3.5% -- Market Talk

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

54.84% upside

12 Months Forecast

Average 16.8 USD 54.84%

High 20 USD

Low 13.6 USD

Based on 2 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Based on 2 analysts giving stock ratings to Hutchison China MediTech Ltd ADR - Dist in the past 3 months.

Sentiment

By Acuity

8 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.